** charts after earnings **
- Reports Q3 (Sep) loss of $0.21 per share, $0.04 better than the Capital IQ Consensus of ($0.25); revenues rose 1440.0% year/year to $6.16 mln vs the $6.47 mln Capital IQ Consensus.
- Revenues primarily included ~$4.0 mln of product sales and $2.2 mln in GALLIPRANT licensing and collaboration revenue. The product sales include $3.2 mln related to GALLIPRANT product sales as finished goods under its supply arrangement with Elanco and $717 thousand in NOCITA net sales. For the nine-month period ended September 30, 2017, Aratana recorded $15.1 mln in net revenues compared to $38.3 mln in the first nine months of 2016, which primarily resulted from the licensing and collaboration revenues under the collaboration agreement with Elanco.
LEAWOOD, Kan. (AP) _ Aratana Therapeutics Inc. (PETX) on Thursday reported a loss of $8.9 million in its third quarter.
On a per-share basis, the Leawood, Kansas-based company said it had a loss of 21 cents.
The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 26 cents per share.
The developer of pet medications posted revenue of $6.2 million in the period.
Aratana shares have fallen 24 percent since the beginning of the year. In the final minutes of trading on Thursday, shares hit $5.46, a drop of 31 percent in the last 12 months.
